Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer

Edith A. Perez, Francois J. Geoffroy, Shauna Hillman, Elizabeth A. Johnson, Gist H. Farr, Henry D. Tazelarr, Alan K. Hatfield, James E. Krook, James A. Maillard, Ralph Levitt, Randolph Stuart Marks

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: This study evaluated the activity and tolerance for the combination of oral etoposide and paclitaxel as first-line therapy for patients with extensive SCLC. Methods: A total of 57 patients were enrolled in this study. A cycle of chemotherapy consisted of oral etoposide administered as 50 mg BID on days 1 through 10 and paclitaxel administered as 150 mg/m2 IV (3 h infusion) along with the first dose of etoposide on day 10. Patients were assessed for response to therapy (regression, stable disease, progression), survival, time to disease progression, and toxicity. Results/conclusions: Fifty-five patients were evaluable for efficacy parameters. Among the 55 patients, there were six with complete regression of disease, 18 with partial regression, 11 with regression, five with stable disease, and 15 with progressive disease, yielding an overall response rate of 63.6% (95% confidence interval, 50.0-76.0%). The 6-month and 1-year progression-free survival rates were 48.2 and 18.9%, respectively. The median time to disease progression was 5.8 months. The overall survival rates were 67.3% at 6 months and 41.8% at 1 year. The combination of oral etoposide and paclitaxel demonstrated significant efficacy as first-line therapy for extensive SCLC, with an overall response rate of 63.6% for 55 evaluable patients. In addition, the treatment was well tolerated with no unexpected toxicities.

Original languageEnglish (US)
Pages (from-to)347-353
Number of pages7
JournalLung Cancer
Volume44
Issue number3
DOIs
StatePublished - Jun 2004

Fingerprint

Small Cell Lung Carcinoma
Etoposide
Paclitaxel
Disease Progression
Survival Rate
Therapeutics
Disease-Free Survival
Confidence Intervals
Drug Therapy
Survival

Keywords

  • Etoposide
  • Oral chemotherapy
  • Paclitaxel
  • Small cell lung cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Perez, E. A., Geoffroy, F. J., Hillman, S., Johnson, E. A., Farr, G. H., Tazelarr, H. D., ... Marks, R. S. (2004). Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer. Lung Cancer, 44(3), 347-353. https://doi.org/10.1016/j.lungcan.2003.12.002

Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer. / Perez, Edith A.; Geoffroy, Francois J.; Hillman, Shauna; Johnson, Elizabeth A.; Farr, Gist H.; Tazelarr, Henry D.; Hatfield, Alan K.; Krook, James E.; Maillard, James A.; Levitt, Ralph; Marks, Randolph Stuart.

In: Lung Cancer, Vol. 44, No. 3, 06.2004, p. 347-353.

Research output: Contribution to journalArticle

Perez, EA, Geoffroy, FJ, Hillman, S, Johnson, EA, Farr, GH, Tazelarr, HD, Hatfield, AK, Krook, JE, Maillard, JA, Levitt, R & Marks, RS 2004, 'Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer', Lung Cancer, vol. 44, no. 3, pp. 347-353. https://doi.org/10.1016/j.lungcan.2003.12.002
Perez, Edith A. ; Geoffroy, Francois J. ; Hillman, Shauna ; Johnson, Elizabeth A. ; Farr, Gist H. ; Tazelarr, Henry D. ; Hatfield, Alan K. ; Krook, James E. ; Maillard, James A. ; Levitt, Ralph ; Marks, Randolph Stuart. / Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer. In: Lung Cancer. 2004 ; Vol. 44, No. 3. pp. 347-353.
@article{102165a2643848708039fc39eb0bbb09,
title = "Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer",
abstract = "Background: This study evaluated the activity and tolerance for the combination of oral etoposide and paclitaxel as first-line therapy for patients with extensive SCLC. Methods: A total of 57 patients were enrolled in this study. A cycle of chemotherapy consisted of oral etoposide administered as 50 mg BID on days 1 through 10 and paclitaxel administered as 150 mg/m2 IV (3 h infusion) along with the first dose of etoposide on day 10. Patients were assessed for response to therapy (regression, stable disease, progression), survival, time to disease progression, and toxicity. Results/conclusions: Fifty-five patients were evaluable for efficacy parameters. Among the 55 patients, there were six with complete regression of disease, 18 with partial regression, 11 with regression, five with stable disease, and 15 with progressive disease, yielding an overall response rate of 63.6{\%} (95{\%} confidence interval, 50.0-76.0{\%}). The 6-month and 1-year progression-free survival rates were 48.2 and 18.9{\%}, respectively. The median time to disease progression was 5.8 months. The overall survival rates were 67.3{\%} at 6 months and 41.8{\%} at 1 year. The combination of oral etoposide and paclitaxel demonstrated significant efficacy as first-line therapy for extensive SCLC, with an overall response rate of 63.6{\%} for 55 evaluable patients. In addition, the treatment was well tolerated with no unexpected toxicities.",
keywords = "Etoposide, Oral chemotherapy, Paclitaxel, Small cell lung cancer",
author = "Perez, {Edith A.} and Geoffroy, {Francois J.} and Shauna Hillman and Johnson, {Elizabeth A.} and Farr, {Gist H.} and Tazelarr, {Henry D.} and Hatfield, {Alan K.} and Krook, {James E.} and Maillard, {James A.} and Ralph Levitt and Marks, {Randolph Stuart}",
year = "2004",
month = "6",
doi = "10.1016/j.lungcan.2003.12.002",
language = "English (US)",
volume = "44",
pages = "347--353",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer

AU - Perez, Edith A.

AU - Geoffroy, Francois J.

AU - Hillman, Shauna

AU - Johnson, Elizabeth A.

AU - Farr, Gist H.

AU - Tazelarr, Henry D.

AU - Hatfield, Alan K.

AU - Krook, James E.

AU - Maillard, James A.

AU - Levitt, Ralph

AU - Marks, Randolph Stuart

PY - 2004/6

Y1 - 2004/6

N2 - Background: This study evaluated the activity and tolerance for the combination of oral etoposide and paclitaxel as first-line therapy for patients with extensive SCLC. Methods: A total of 57 patients were enrolled in this study. A cycle of chemotherapy consisted of oral etoposide administered as 50 mg BID on days 1 through 10 and paclitaxel administered as 150 mg/m2 IV (3 h infusion) along with the first dose of etoposide on day 10. Patients were assessed for response to therapy (regression, stable disease, progression), survival, time to disease progression, and toxicity. Results/conclusions: Fifty-five patients were evaluable for efficacy parameters. Among the 55 patients, there were six with complete regression of disease, 18 with partial regression, 11 with regression, five with stable disease, and 15 with progressive disease, yielding an overall response rate of 63.6% (95% confidence interval, 50.0-76.0%). The 6-month and 1-year progression-free survival rates were 48.2 and 18.9%, respectively. The median time to disease progression was 5.8 months. The overall survival rates were 67.3% at 6 months and 41.8% at 1 year. The combination of oral etoposide and paclitaxel demonstrated significant efficacy as first-line therapy for extensive SCLC, with an overall response rate of 63.6% for 55 evaluable patients. In addition, the treatment was well tolerated with no unexpected toxicities.

AB - Background: This study evaluated the activity and tolerance for the combination of oral etoposide and paclitaxel as first-line therapy for patients with extensive SCLC. Methods: A total of 57 patients were enrolled in this study. A cycle of chemotherapy consisted of oral etoposide administered as 50 mg BID on days 1 through 10 and paclitaxel administered as 150 mg/m2 IV (3 h infusion) along with the first dose of etoposide on day 10. Patients were assessed for response to therapy (regression, stable disease, progression), survival, time to disease progression, and toxicity. Results/conclusions: Fifty-five patients were evaluable for efficacy parameters. Among the 55 patients, there were six with complete regression of disease, 18 with partial regression, 11 with regression, five with stable disease, and 15 with progressive disease, yielding an overall response rate of 63.6% (95% confidence interval, 50.0-76.0%). The 6-month and 1-year progression-free survival rates were 48.2 and 18.9%, respectively. The median time to disease progression was 5.8 months. The overall survival rates were 67.3% at 6 months and 41.8% at 1 year. The combination of oral etoposide and paclitaxel demonstrated significant efficacy as first-line therapy for extensive SCLC, with an overall response rate of 63.6% for 55 evaluable patients. In addition, the treatment was well tolerated with no unexpected toxicities.

KW - Etoposide

KW - Oral chemotherapy

KW - Paclitaxel

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=2342537018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342537018&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2003.12.002

DO - 10.1016/j.lungcan.2003.12.002

M3 - Article

C2 - 15140548

AN - SCOPUS:2342537018

VL - 44

SP - 347

EP - 353

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -